3D Communications Expands Market Access and Reimbursement Communications Services for Pharmaceutical Companies. Senior Executive Jane Horvath Joins 3D to Lead Program
Source: 3D Communications
3D Communications announced today that it has significantly expanded its process for helping pharmaceutical companies communicate the value of their drugs and maximize patient access. The newly expanded 3D Market Access and Reimbursement Communications services will go beyond helping companies develop and deliver their “Value Story”. It will also provide a process to identify and engage critical stakeholders earlier in the “innovation-to-market” timeline, and incorporate critical learnings throughout the development process.
“Getting FDA approval used to be the major obstacle pharmaceutical companies had to overcome to get a drug to market,” said 3D Founding Partner, Cindy DiBiasi. “Today, companies must also demonstrate a drug’s value to multiple audiences in order to justify pricing and maximize its reimbursement and access to patients. Without proving that value, patients, the healthcare system, and pharmaceutical companies all lose.”
To lead the newly-enhanced team of market access, communications, science, and stakeholder experts, 3D has hired Jane Horvath. Previously, Jane was the Executive Director of Health Policy and Reimbursement at Merck & Co. and a Vice President at Breakaway Policy Strategies.
“Global pharmaceutical markets are undergoing a seismic shift,” said Horvath. “Because of that, the old way of thinking about how to price a drug and talk about its value doesn’t work anymore. I’m excited about this opportunity at 3D, because the process allows us to assess what’s important to patients, physicians, and payers and help pharmaceutical companies integrate and communicate the value of their products in terms of how patients feel, function and/or live.”
3D’s Market Access and Reimbursement Communications program has been built on the company’s proprietary 3D ACT® (Analysis, Content Development, Testing) process, which has helped companies win approval at FDA Advisory Committee meetings for more than a decade.
“We’re excited to have Jane on our team because she understands pharma, the issues, and the environment – and she is extremely forward-thinking, said DiBiasi. “Jane’s expertise, combined with our 3D ACT® process, will help our clients succeed in this new Market Access reality.”
In addition to her work in pharma, Jane held a series of high-profile government positions including Deputy Assistant Secretary for Legislation in the US Department of Health and Human Services where she was responsible for legislative policy for all health-related areas, including Medicare, Medicaid, and prescription drug pricing.